<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461734</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT-PACE Version 4</org_study_id>
    <nct_id>NCT00461734</nct_id>
  </id_info>
  <brief_title>PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing</brief_title>
  <acronym>PROTECT-PACE</acronym>
  <official_title>PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing. Does Right Ventricular High-septal Pacing Improve Outcome Compared With Right Ventricular Apical Pacing?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be done in patients who require the implantation of a cardiac pacemaker (an
      electronic device that controls the heartbeat) for complete heart block (a heart rhythm
      abnormality resulting in a slow heart beat). Pacemakers regulate the heart beat by delivering
      pulses of electricity through special wires (pacing leads) which are placed inside the heart.

      This study will compare two groups of pacemaker patients. Each group will have their pacing
      leads placed in a particular location in the heart. The purpose of the study is to show
      whether the position used in one group is better for maintaining effective heart function
      compared to the position used in the other group.

      The leads in one group will be placed in a position called the Right Ventricular Apex. This
      is the traditional and most frequently used position for pacemaker leads.

      The leads in the other group will be placed in a position called the Right Ventricular High
      Septum. This is a less commonly used position, but may result in health benefits for the
      patients compared with the Right Ventricular Apex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an increasing amount of evidence to suggest that other positions in the heart may be
      more effective than the conventional Right Ventricular Apex (RVA) position for restoring good
      heart function. The best site to place a lead has not yet been proven.

      This is a study comparing the long term clinical effects of two different lead positions. The
      measurements taken to assess the clinical effects include:

        -  the effectiveness of the heart's pumping action (as measured by ultrasound scans)

        -  measurements of how far patients can walk in 6 minutes

        -  analysis of blood samples

        -  collection of information from the pacemaker about heart rhythm problems

      Half of the patients in the study will receive conventional leads placed in the more common
      RVA position in the heart. The other half will receive a relatively new type of lead placed
      in what is called the Right Ventricular High Septal (RVHS) position.

      In order to fairly compare the outcomes of these two different lead positions this study has
      been designed as a 'randomized', 'blind' trial. This means that the group which patients will
      be entered into will be chosen at random and patients will not be told which group they are
      in.

      Patients will each have an equal (50:50) chance of being in either group. By carefully
      comparing the clinical differences between the two groups of patients, the study aims to
      prove whether or not there are additional benefits for patients when the RVHS lead position
      is used.

      All leads used in the study have been shown to be safe for patients and are available
      commercially for implantation. All of the implanting doctors involved in the study are
      experienced at implanting the pacemakers and leads that will be used in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort).</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Per Protocol Cohort).</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Intent to Treat Cohort)</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Per Protocol Cohort)</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Intent to Treat Cohort)</measure>
    <time_frame>At 5-years follow-up (study extension)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Per Protocol Cohort)</measure>
    <time_frame>At 5-year follow-up (study extension)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening of Heart Failure</measure>
    <time_frame>At 5-year follow-up (study extension)</time_frame>
    <description>Worsening of heart failure can be defined as:
Heart failure-related hospitalization requiring intravenous heart failure therapy, or
Emergency department visit for heart failure requiring intravenous heart failure therapy, or
Any other visit in which the patient presents with signs or symptoms consistent with heart failure or heart failure exacerbation or marked decline in ejection fraction &lt;35%, and intravenous heart failure therapy is required or titrate therapy.
CRT-P or CRT-D upgrade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>At 5-year follow-up (study extension)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stroke</measure>
    <time_frame>At 5-year follow-up (study extension)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide Levels (Intent to Treat Cohort)</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide Levels (Per Protocol Cohort)</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Measures of Left Ventricular Dyssynchrony</measure>
    <time_frame>At 2-year follow-up</time_frame>
    <description>No analysis has been done for this section since that variable was not collected during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Hall-Walk Distance (Intent to Treat Cohort)</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Hall-Walk Distance (Per Protocol Cohort)</measure>
    <time_frame>At 2-year follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>RV Apex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RV High Septum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RV lead placement site</intervention_name>
    <description>Patients randomised to RV apical or high septal lead placement site</description>
    <arm_group_label>RV Apex</arm_group_label>
    <arm_group_label>RV High Septum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with high grade AV block and sinus rhythm, scheduled to undergo dual chamber
             pacemaker implantation OR patients with high grade AV block and permanent atrial
             fibrillation, scheduled to undergo single chamber ventricular pacemaker implantation.

          -  Patients aged 18 years or older.

        Exclusion Criteria:

          -  Patients indicated for an Implantable Cardioverter Defibrillator or Cardiac
             Resynchronization Therapy.

          -  Patients following junctional ablation.

          -  Patients with a Myocardial Infarction within three months prior to enrollment.

          -  Patients that received bypass surgery within three months prior to enrollment.

          -  Patients that had a valve replacement within three months prior to enrollment or
             patients with a mechanical right heart valve.

          -  Patients where a right ventricular lead cannot be placed i.e. complex congenital heart
             disease.

          -  Patients with hypertrophic obstructive cardiomyopathy.

          -  Patients with acute coronary syndrome, unstable angina, severe mitral regurgitation
             and/or hemodynamically significant aortic stenosis.

          -  Previous implanted pacemaker or cardioverter defibrillator.

          -  Known paroxysmal atrial fibrillation or a documented episode of atrial fibrillation
             prior to enrollment.

          -  Patients on amiodarone therapy within the last six months prior to enrollment.

          -  Terminal conditions with a life expectancy of less than two years.

          -  Participation in any other study that would confound the results of this study.

          -  Psychological or emotional problems that may interfere with the volunteer's ability to
             provide full consent or fully understand the purposes of the study.

          -  Pregnant patients or patients who may become pregnant during the time-scale of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Gerald Kaye</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Alexandra Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Womens' Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Wakefield Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester General</name>
      <address>
        <city>Colchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Orpington, Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <results_first_submitted>September 15, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Right Ventricular High Septal Pacing</keyword>
  <keyword>Right Ventricular Apical Pacing</keyword>
  <keyword>Left Ventricular Dysfunction</keyword>
  <keyword>Heart Block</keyword>
  <keyword>Pacemaker</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Partecipants initially assessed for eligibility were 248 of whom 8 were excluded before the randomization due to the following causes:
4 failed inclusion/exclusion criteria
2 cheanged medical condition resulting no longer eligible
1 had a non-pacemaker procedure
1 the site was aware of his/her randomization code in the envelope</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RV Apex</title>
          <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
        </group>
        <group group_id="P2">
          <title>RV High Septum</title>
          <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RV Apex</title>
          <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
        </group>
        <group group_id="B2">
          <title>RV High Septum</title>
          <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.7" spread="11.1"/>
                    <measurement group_id="B2" value="74.7" spread="10"/>
                    <measurement group_id="B3" value="74.2" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort).</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Intent to Treat Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site (Intent to treat cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site (Intent to treat cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort).</title>
          <population>Intent to Treat Cohort with data available</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="10.5"/>
                    <measurement group_id="O2" value="-3.43" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4347</p_value>
            <method>two-sided z-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Per Protocol Cohort).</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Per Protocol Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients effectively had RV apical lead placement site (Per protocol cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients effectively had RV high septal lead placement site (Per protocol cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Per Protocol Cohort).</title>
          <population>Per Protocol Cohort with data available</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="10.4"/>
                    <measurement group_id="O2" value="-3.60" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.338</p_value>
            <method>two-sided z-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Intent to Treat Cohort)</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Intent to Treat Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site (Intent to treat cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site (Intent to treat cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Intent to Treat Cohort)</title>
          <population>Intent to Treat Cohort with data available</population>
          <units>minutes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.47" spread="22.61"/>
                    <measurement group_id="O2" value="24.11" spread="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2257</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Per Protocol Cohort)</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Per Protocol Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients effectively had RV apical lead placement site (Per protocol cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients effectively had RV high septal lead placement site (Per protocol cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Per Protocol Cohort)</title>
          <population>Per Protocol Cohort with data available</population>
          <units>minutes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.98" spread="20.04"/>
                    <measurement group_id="O2" value="6.66" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5480</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Intent to Treat Cohort)</title>
        <time_frame>At 5-years follow-up (study extension)</time_frame>
        <population>Intent to Treat Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site (Intent to treat cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site (Intent to treat cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Intent to Treat Cohort)</title>
          <population>Intent to Treat Cohort with data available</population>
          <units>minutes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.73" spread="11.95"/>
                    <measurement group_id="O2" value="63.83" spread="36.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8868</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Per Protocol Cohort)</title>
        <time_frame>At 5-year follow-up (study extension)</time_frame>
        <population>Per Protocol Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients effectively had RV apical lead placement site (Per protocol cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients effectively had RV high septal lead placement site (Per protocol cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Atrial Tachyarrhythmia Recorded by the Pacemakers (Per Protocol Cohort)</title>
          <population>Per Protocol Cohort with data available</population>
          <units>minutes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.75" spread="36.21"/>
                    <measurement group_id="O2" value="18.61" spread="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6151</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worsening of Heart Failure</title>
        <description>Worsening of heart failure can be defined as:
Heart failure-related hospitalization requiring intravenous heart failure therapy, or
Emergency department visit for heart failure requiring intravenous heart failure therapy, or
Any other visit in which the patient presents with signs or symptoms consistent with heart failure or heart failure exacerbation or marked decline in ejection fraction &lt;35%, and intravenous heart failure therapy is required or titrate therapy.
CRT-P or CRT-D upgrade.</description>
        <time_frame>At 5-year follow-up (study extension)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
          </group>
        </group_list>
        <measure>
          <title>Worsening of Heart Failure</title>
          <description>Worsening of heart failure can be defined as:
Heart failure-related hospitalization requiring intravenous heart failure therapy, or
Emergency department visit for heart failure requiring intravenous heart failure therapy, or
Any other visit in which the patient presents with signs or symptoms consistent with heart failure or heart failure exacerbation or marked decline in ejection fraction &lt;35%, and intravenous heart failure therapy is required or titrate therapy.
CRT-P or CRT-D upgrade.</description>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>At 5-year follow-up (study extension)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Stroke</title>
        <time_frame>At 5-year follow-up (study extension)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Stroke</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Natriuretic Peptide Levels (Intent to Treat Cohort)</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Intent to Treat Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site (Intent to treat cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site (Intent to trat cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Natriuretic Peptide Levels (Intent to Treat Cohort)</title>
          <population>Intent to Treat Cohort with data available</population>
          <units>picograms per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" lower_limit="0.3" upper_limit="1428"/>
                    <measurement group_id="O2" value="111.3" lower_limit="0.3" upper_limit="1536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0525</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Natriuretic Peptide Levels (Per Protocol Cohort)</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Per Protocol Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients effectively had RV apical lead placement site (Per protocol cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients effectively had RV high septal lead placement site (Per protocol cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Natriuretic Peptide Levels (Per Protocol Cohort)</title>
          <population>Per Protocol Cohort with data available</population>
          <units>picograms per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.6" lower_limit="0.3" upper_limit="1428"/>
                    <measurement group_id="O2" value="110.8" lower_limit="0.3" upper_limit="1429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1852</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Echocardiographic Measures of Left Ventricular Dyssynchrony</title>
        <description>No analysis has been done for this section since that variable was not collected during the study.</description>
        <time_frame>At 2-year follow-up</time_frame>
        <population>No analysis has been done for this section since that variable was not collected during the study</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
          </group>
        </group_list>
        <measure>
          <title>Echocardiographic Measures of Left Ventricular Dyssynchrony</title>
          <description>No analysis has been done for this section since that variable was not collected during the study.</description>
          <population>No analysis has been done for this section since that variable was not collected during the study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Hall-Walk Distance (Intent to Treat Cohort)</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Intent to Treat Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients randomised to RV apical lead placement site (Intent to treat cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients randomised to RV high septal lead placement site (Intent to treat cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Hall-Walk Distance (Intent to Treat Cohort)</title>
          <population>Intent to Treat Cohort with data available</population>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391" lower_limit="307" upper_limit="475"/>
                    <measurement group_id="O2" value="395" lower_limit="320" upper_limit="463.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9719</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Hall-Walk Distance (Per Protocol Cohort)</title>
        <time_frame>At 2-year follow-up</time_frame>
        <population>Per Protocol Cohort with data available</population>
        <group_list>
          <group group_id="O1">
            <title>RV Apex</title>
            <description>RV lead placement site: Patients effectively had RV apical lead placement site (Per protocol cohort)</description>
          </group>
          <group group_id="O2">
            <title>RV High Septum</title>
            <description>RV lead placement site: Patients effectively had RV high septal lead placement site (Per protocol cohort)</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Hall-Walk Distance (Per Protocol Cohort)</title>
          <population>Per Protocol Cohort with data available</population>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.5" lower_limit="304.5" upper_limit="477.5"/>
                    <measurement group_id="O2" value="426.5" lower_limit="355.5" upper_limit="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8779</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RV Apex</title>
          <description>RV lead placement site: Patients randomised to RV apical lead placement site</description>
        </group>
        <group group_id="E2">
          <title>RV High Septum</title>
          <description>RV lead placement site: Patients randomised to RV high septal lead placement site</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SOB</sub_title>
                <counts group_id="E1" events="34" subjects_affected="25" subjects_at_risk="120"/>
                <counts group_id="E2" events="50" subjects_affected="29" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>product issue</sub_title>
                <description>Adverse events related to the pacemaker (e.g., lead dislodgment or changing in threshold values). The term 'product issue' is taken from MedDRA 19.0 classification.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>diabets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>bile duct</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>trauma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>angiography</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>carcinoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>prostate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>bypass</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>raynaud's disease</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gerald Kaye</name_or_title>
      <organization>Princess Alexandra Hospital</organization>
      <phone>07 3176 2111</phone>
      <email>gerald.kaye@health.qld.gov.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

